HST5040 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
245	プロピオン酸血症	1
246	メチルマロン酸血症	1

245. プロピオン酸血症

---

臨床試験数 : 13 /  薬物数 : 17 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 6

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04732429 (ClinicalTrials.gov)	March 15, 2021	21/1/2021	Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia	A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study	Methylmalonic Acidemia;Propionic Acidemia	Drug: HST5040;Drug: Placebo	HemoShear Therapeutics	NULL	Recruiting	2 Years	N/A	All	12	Phase 2	United States

246. メチルマロン酸血症

---

臨床試験数 : 19 /  薬物数 : 26 - (DrugBank : 3) / 標的遺伝子数 : 17 - 標的パスウェイ数 : 23

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04732429 (ClinicalTrials.gov)	March 15, 2021	21/1/2021	Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia	A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study	Methylmalonic Acidemia;Propionic Acidemia	Drug: HST5040;Drug: Placebo	HemoShear Therapeutics	NULL	Recruiting	2 Years	N/A	All	12	Phase 2	United States